Sturm Ruger Stock To Go Ex-dividend Tomorrow (RGR)

NEW YORK ( TheStreet) -- The ex-dividend date for Sturm Ruger & Company (NYSE: RGR) is tomorrow, March 7, 2012. Owners of shares as of market close today will be eligible for a dividend of 21 cents per share. At a price of $41.73 as of 9:30 a.m. ET, the dividend yield is 2%.

The average volume for Sturm Ruger has been 189,000 shares per day over the past 30 days. Sturm Ruger has a market cap of $733.3 million and is part of the consumer goods sector and consumer durables industry. Shares are up 26.5% year to date as of the close of trading on Monday.

Sturm, Ruger & Company, Inc. engages in the design, manufacture, and sale of firearms in the United States. It offers single-shot, autoloading, bolt-action, and sporting rifles; shotguns; rim fire autoloading and center fire autoloading pistols; and single-action and double-action revolvers. The company has a P/E ratio of 20.5, below the average consumer durables industry P/E ratio of 21 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Sturm Ruger as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Sturm Ruger Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing